-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
After the recent successes of Pfizer and Merck, the failed COVID-19 drugs were forgotten by the industry
More than a year ago, Roche and Atea signed a $350 million cooperation agreement for the oral antiviral drug AT-527
However, a key Phase 2 clinical trial in patients with mild to moderate COVID-19 that was published in October this year did not meet the primary endpoint
Roche still seems to be working with Atea, despite failures and delays
The COVID-19 activities mentioned by Roche include its internal diagnostic work and the antibody cocktail therapy Ronapreve developed in cooperation with Regeneron.
Due to Roche’s withdrawal, all rights and licenses previously granted to Roche by Atea will be returned to Atea.
Although Roche has left, Atea has not yet abandoned the AT-527 project, saying that it is still conducting Phase 3 trials and expects to obtain data in the second half of 2022
However, it may be too late
If these oral drugs, together with other drugs from other pharmaceutical companies (such as GlaxoSmithKline/Vir), prove to be sufficient in the real world to prevent death and serious illness from COVID-19, then it will be like ours in the COVID-19 vaccine As you have seen, the demand for such treatments may plummet
Reference source: As Merck and Pfizer predict incoming billions from their COVID drugs, Roche culls pandemic ties with Atea
